Sarah Prinsloo1, Diane Novy2, Larry Driver2, Randall Lyle3, Lois Ramondetta4, Cathy Eng5, Jennifer McQuade6, Gabriel Lopez1, Lorenzo Cohen1. 1. Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Marriage and Family Therapy, Mount Mercy University, Cedar Rapids, Iowa. 4. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND:Chemotherapy-induced peripheral neuropathy (CIPN) is a significant problem for cancer patients, and there are limited treatment options for this often debilitating condition. Neuromodulatory interventions could be a novel modality for patients trying to manage CIPN symptoms; however, they are not yet the standard of care. This study examined whether electroencephalogram (EEG) neurofeedback (NFB) could alleviate CIPN symptoms in survivors. METHODS: This was a randomized controlled trial with survivors assigned to an NFB group or a wait-list control (WLC) group. The NFB group underwent 20 sessions of NFB, in which visual and auditory rewards were given for voluntary changes in EEGs. The Brief Pain Inventory (BPI) worst-pain item was the primary outcome. The BPI, the Pain Quality Assessment Scale, and EEGs were collected before NFB and again after treatment. Outcomes were assessed with general linear modeling. RESULTS:Cancer survivors with CIPN (average duration of symptoms, 25.3 mo), who were mostly female and had a mean age of 62.5 years, were recruited between April 2011 and September 2014. One hundred percent of the participants starting the NFB program completed it (30 in the NFB group and 32 in the WLC group). The NFB group demonstrated greater improvement than the controls on the BPI worst-pain item (mean change score, -2.43 [95% confidence interval, -3.58 to -1.28] vs 0.09 [95% confidence interval, -0.72 to -0.90]; P =·.001; effect size, 0.83). CONCLUSIONS:NFB appears to be effective at reducing CIPN symptoms. There was evidence of neurological changes in the cortical location and in the bandwidth targeted by the intervention, and changes in EEG activity were predictive of symptom reduction. Cancer 2017;123:1989-1997.
RCT Entities:
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant problem for cancerpatients, and there are limited treatment options for this often debilitating condition. Neuromodulatory interventions could be a novel modality for patients trying to manage CIPN symptoms; however, they are not yet the standard of care. This study examined whether electroencephalogram (EEG) neurofeedback (NFB) could alleviate CIPN symptoms in survivors. METHODS: This was a randomized controlled trial with survivors assigned to an NFB group or a wait-list control (WLC) group. The NFB group underwent 20 sessions of NFB, in which visual and auditory rewards were given for voluntary changes in EEGs. The Brief Pain Inventory (BPI) worst-pain item was the primary outcome. The BPI, the Pain Quality Assessment Scale, and EEGs were collected before NFB and again after treatment. Outcomes were assessed with general linear modeling. RESULTS:Cancer survivors with CIPN (average duration of symptoms, 25.3 mo), who were mostly female and had a mean age of 62.5 years, were recruited between April 2011 and September 2014. One hundred percent of the participants starting the NFB program completed it (30 in the NFB group and 32 in the WLC group). The NFB group demonstrated greater improvement than the controls on the BPI worst-pain item (mean change score, -2.43 [95% confidence interval, -3.58 to -1.28] vs 0.09 [95% confidence interval, -0.72 to -0.90]; P =·.001; effect size, 0.83). CONCLUSIONS: NFB appears to be effective at reducing CIPN symptoms. There was evidence of neurological changes in the cortical location and in the bandwidth targeted by the intervention, and changes in EEG activity were predictive of symptom reduction. Cancer 2017;123:1989-1997.
Authors: Thomas M Atkinson; Tito R Mendoza; Laura Sit; Steven Passik; Howard I Scher; Charles Cleeland; Ethan Basch Journal: Pain Med Date: 2010-01-15 Impact factor: 3.750
Authors: Ellen M Lavoie Smith; Herbert Pang; Constance Cirrincione; Stewart Fleishman; Electra D Paskett; Tim Ahles; Linda R Bressler; Camilo E Fadul; Chetaye Knox; Nguyet Le-Lindqwister; Paul B Gilman; Charles L Shapiro Journal: JAMA Date: 2013-04-03 Impact factor: 56.272
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Mark P Jensen; Arnold R Gammaitoni; David O Olaleye; Napoleon Oleka; Srinivas R Nalamachu; Bradley S Galer Journal: J Pain Date: 2006-11 Impact factor: 5.820
Authors: Michael D Stubblefield; Harold J Burstein; Allen W Burton; Christian M Custodio; Gary E Deng; Maria Ho; Larry Junck; G Stephen Morris; Judith A Paice; Sudhakar Tummala; Jamie H Von Roenn Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith Journal: Support Care Cancer Date: 2019-06-17 Impact factor: 3.603
Authors: Jessica N Mezzanotte; Michael Grimm; Namrata V Shinde; Timiya Nolan; Lise Worthen-Chaudhari; Nicole O Williams; Maryam B Lustberg Journal: Curr Treat Options Oncol Date: 2022-02-15
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315
Authors: Kaitlin H Chung; Susanna B Park; Fiona Streckmann; Joachim Wiskemann; Nimish Mohile; Amber S Kleckner; Luana Colloca; Susan G Dorsey; Ian R Kleckner Journal: Cancers (Basel) Date: 2022-02-26 Impact factor: 6.575
Authors: Maryam Omran; Elizabeth K Belcher; Nimish A Mohile; Shelli R Kesler; Michelle C Janelsins; Andrea G Hohmann; Ian R Kleckner Journal: Front Mol Biosci Date: 2021-06-11